Graft Inflow Modulation for Portal Hyper-perfusion in Live Donor Liver Transplantation
Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Jan 31, 2020
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
Due to shortage of deceased donor organs, LDLT (living donor living transplantation) is gaining importance all over world. Previous studies have showed poor outcomes with donor grafts having GRWR (graft to recipient weight ratio) \< 0.8 due to development of SFSS (Small for Size Syndrome) where the graft is too small to meet the recipient's metabolic demands. SFSS is characterised by prolonged cholestasis, intractable ascites, prolonged INR and encephalopathy. However, it is not always possible to obtain larger graft from live donor owing to the risk's associated to donor. Various technique...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Portal Venous Pressure (PVP) \> 15 mm Hg after reperfusion or
- • Portal venous flow (PVF) \> 250 ml/min/100 gr of liver after reperfusion with a gradient (PVP - CVP) of ≥ 7 mm Hg
- Exclusion Criteria:
- • Significant peripancreatic collaterals preventing safe access to splenic artery
- • Acute Liver Failure as an indication for transplant
- • ABO incompatible transplants
- • Pediatric transplants
- • Refusal to participate in the study
About Institute Of Liver And Biliary Sciences, India
The Institute of Liver and Biliary Sciences (ILBS) in India is a premier research and healthcare institution dedicated to the advancement of knowledge and treatment in liver, biliary, and related diseases. As a clinical trial sponsor, ILBS is committed to conducting innovative and ethically-driven research to improve patient outcomes and enhance therapeutic options in hepatology. The institute fosters collaboration among multidisciplinary teams of clinicians, researchers, and healthcare professionals, ensuring rigorous scientific methodologies and adherence to regulatory standards. Through its focus on translational research, ILBS aims to bridge the gap between laboratory discoveries and clinical applications, ultimately contributing to the global understanding and management of liver diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, , India
Patients applied
Trial Officials
Gattu Tharun, MS
Principal Investigator
Senior resident, Department of HPB surgery, ILBS, India
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials